A week dedicated to Nuclear Medicine & Molecular Imaging

London, October 2015: Nuclear Medicine & Molecular Imaging Week is between 4 and 10 October 2015. Each year, the SNMMI and SNMMI-TS join forces with the nuclear medicine and molecular imaging community to gain recognition and support for the field. Celebrated during the first full week of October, Nuclear Medicine Week encourages community members to take pride in their profession – recognising their colleagues for their hard work and promoting nuclear medicine to the entire medical community as well as to the public. Imaging technologies have long had a key role in clinical diagnostics and biomedical research. Due to its noninvasive nature and exquisite sensitivity, molecular imaging is of particular relevance when it comes to the drug development process, translational science and validation of new targets in both preclinical disease models and human clinical trials. Imanova is an expert within imaging sciences and their application to the drug development process, and welcomes initiatives like the Nuclear Medicine Week to raise awareness and drive greater understanding of application of imaging techniques beyond diagnostic applications. The cost of developing a prescription drug that gains market approval is now estimated at $2.6 billion. However, only one-in-ten novel therapeutics entering the clinic obtains approval by the U.S. Food and Drug Administration. “A well-designed imaging study saves time and cost,” said Imanova CEO Kevin Cox. “For example, molecular imaging provides early information in man that de-risks decision making and can help make early clinical trials shorter, smaller and more targeted, bringing drugs to the market more quickly and more cost-effectively.” In an effort to increase knowledge and understanding about Molecular Imaging, Imanova publishes a number of academic papers and delivers a number of presentation at industry events around the world. To find out more about Imanova and its work within imaging sciences, visit www.imanova.co.uk.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.